Generated Narrative: Citation

StructureDefinition Work Group: cds

url: https://fevir.net/resources/Citation/179559

identifier: FEvIR Object Identifier: 179559

version: 1.0.0-ballot

title: DatasetCitation: Extrachromosomal DNA Amplification Contributes to Small Cell Lung Cancer Heterogeneity and is Associated with Worse Outcomes

status: active

date: 2023-12-17 16:55:23+0000

publisher: HL7 International / Clinical Decision Support

contact: HL7 International / Clinical Decision Support: http://www.hl7.org/Special/committees/dss

description: This Citation Resource is referenced in an example for the EBMonFHIR Implementation Guide.

jurisdiction: World (m49.htm#001)

copyright: https://creativecommons.org/licenses/by-nc-sa/4.0/

author: Brian S. Alper:

Summaries

citedArtifact

identifier: dbGaP Study Accession: phs003190.v1.p1

Titles

-	Type	Language	Text
*	Primary title (Title Type#primary)	English (Tags for the Identification of Languages#en)	Extrachromosomal DNA Amplification Contributes to Small Cell Lung Cancer Heterogeneity and is Associated with Worse Outcomes

Abstracts

-	Type	Language	Text
*	Study Description (Evidence Based Medicine on FHIR Implementation Guide Code System#description "Description")	English (Tags for the Identification of Languages#en)	Small-cell lung cancer (SCLC) is a very aggressive neuroendocrine lung cancer often associated with oncogenic MYC amplifications, which are known to drive SCLC heterogeneity marked by neuroendocrine (NE) and non-neuroendocrine (non-NE) cell states. The genetic mechanisms of MYC amplification and phenotypic plasticity between cell states is not known. Using data from cell-lines and a few patient-derived samples along with integrated whole-genome sequencing, long-range optical mapping, single-cell DNA sequencing, and fluorescence in situ hybridization, we have attempted to successfully characterize extrachromosomal DNA (ecDNA) as the primary source of MYC amplifications and driver fusions in SCLC. Study Design: Cross-Sectional Study Type: Observational Total number of consented subjects: 5

publicationForm

PublishedIns

-	Type	Identifier	Title	Publisher	PublisherLocation
*	Database (Published In Type#D019991)	Abbreviation: dbGaP	database of Genotypes and Phenotypes	: NLM	Bethesda, MD, USA

citedMedium: Internet (Cited Medium#internet)

articleDate: 2023-10-16

accessionNumber: phs003190.v1.p1

pageCount: Total number of consented subjects: 5

copyright: Data access provided by: dbGaP Authorized Access. For publicly available data (public ftp), Connect to the public download site. The site contains release notes and manifests. The site also contains data dictionaries, variable summaries, documents, and truncated analyses, whenever available.

webLocation

classifier: Webpage (Artifact Url Classifier#webpage)

url: https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs003190.v1.p1

webLocation

classifier: public download site (Evidence Based Medicine on FHIR Implementation Guide Code System#defined-in-text "Defined in text")

url: https://ftp.ncbi.nlm.nih.gov/dbgap/studies/phs003190/phs003190.v1.p1

classification

type: Knowledge Artifact Type (Cited Artifact Classification Type#knowledge-artifact-type)

classifier: Dataset (Citation Artifact Classifier#D064886)

classification

type: Study Design (Evidence Based Medicine on FHIR Implementation Guide Code System#study-design)

classifier: Cross-Sectional (Scientific Evidence Code System (SEVCO) -- EXAMPLE VERSION for EBMonFHIR Implementation Guide#SEVCO:01027 "Cross sectional data collection"), Observational Research (Scientific Evidence Code System (SEVCO) -- EXAMPLE VERSION for EBMonFHIR Implementation Guide#SEVCO:01002 "observational research")

classification

type: Primary Phenotype (Evidence Based Medicine on FHIR Implementation Guide Code System#defined-in-text "Defined in text")

classifier: Small Cell Lung Carcinoma (Evidence Based Medicine on FHIR Implementation Guide Code System#defined-in-text "Defined in text")

contributorship

complete: true

entry

contributor:

name: Anish Thomas

affiliation: : Developmental Therapeutics Branch, Center for Cancer Research, National Cancer Institute, Bethesda, MD, USA

contributionType: Principal Investigator (Evidence Based Medicine on FHIR Implementation Guide Code System#principal-investigator)

role: Author/Creator (Contributor Role#author)

entry

contributor:

name: Lorinc S. Pongor

affiliation: : Developmental Therapeutics Branch, Center for Cancer Research, National Cancer Institute, Bethesda, MD, USA

contributionType: Co-Investigator (Evidence Based Medicine on FHIR Implementation Guide Code System#co-investigator)

role: Author/Creator (Contributor Role#author)

entry

contributor:

name: Rajesh Kumar

affiliation: : Developmental Therapeutics Branch, Center for Cancer Research, National Cancer Institute, Bethesda, MD, USA

contributionType: Co-Investigator (Evidence Based Medicine on FHIR Implementation Guide Code System#co-investigator)

role: Author/Creator (Contributor Role#author)

entry

contributor:

name: Parth Desai

affiliation: : Developmental Therapeutics Branch, Center for Cancer Research, National Cancer Institute, Bethesda, MD, USA

contributionType: Co-Investigator (Evidence Based Medicine on FHIR Implementation Guide Code System#co-investigator)

role: Author/Creator (Contributor Role#author)

Generated Narrative: Practitioner #contributor0

name: Anish Thomas

Generated Narrative: Practitioner #contributor1

name: Lorinc S. Pongor

Generated Narrative: Practitioner #contributor2

name: Rajesh Kumar

Generated Narrative: Practitioner #contributor3

name: Parth Desai